Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

Longeveron (NASDAQ: LGVN) announced that its Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will speak at the Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., December 8-10, 2025.

Rhea-AI Summary

Longeveron (NASDAQ: LGVN) announced that its Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will speak at the Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., December 8-10, 2025.

The executives will join multiple panel discussions on cell therapy for heart failure, including delivery routes, cell types (mesenchymal stem cell therapy for dilated cardiomyopathy referencing POSEIDON and PATH AHEAD), and multi‑stakeholder debate on streamlining cell therapy innovation while maintaining evidence standards.

Argus Dec 3 session

-1.16% close to close Open Argus

Details

News Market Reaction – LGVN

On Dec 3, the day this news came out, LGVN closed 1.16% below the previous close.

Data tracked by StockTitan Argus for the Dec 3 session.

Market Context

This announcement highlights added scientific visibility for Longeveron at the CVCT Forum, with seni...

Analysis

This announcement highlights added scientific visibility for Longeveron at the CVCT Forum, with senior leaders contributing to discussions on cell therapy delivery, cell selection, and heart failure strategy. It follows recent Alzheimer’s data and patent grants that expand protection into the late 2030s. Investors may watch how this visibility supports partnerships, clinical enrollment, and any follow-on updates to the company’s financial and regulatory disclosures.

Key Figures

CVCT Forum dates: December 8–10, 2025 Current price: $0.627 52-week range: $0.58–$2.24 +1 more

CVCT Forum dates

December 8–10, 2025

Global CardioVascular Clinical Trialists Forum schedule

Current price

$0.627

Pre-news trading level on 2025-12-03

52-week range

$0.58–$2.24

52-week low and high before this announcement

Market cap

$13,379,983

Equity value prior to the CVCT speaking news

Historical Context

5 past events · Latest: Dec 03

5 events

1. Dec 03

   Conference speaking invite

   24h Move

   -1.2%

   Executives selected for multiple CVCT panels on cell therapy in heart failure.

2. Dec 02

   Patent grant Canada

   24h Move

   +2.2%

   Canadian patent issued for laromestrocel in frailty and NIDCM through 2037.

3. Dec 01

   Alzheimer’s biomarker data

   24h Move

   -5.1%

   Phase 2 CLEAR MIND MRI data showed reduced neuroinflammation vs placebo.

4. Nov 19

   Alzheimer’s poster selection

   24h Move

   -4.0%

   Laromestrocel poster on neuroinflammation accepted for CTAD 2025 presentation.

5. Nov 12

   U.S. patent grant

   24h Move

   -1.3%

   U.S. patent granted for treating aging-related frailty with inflammaging using MSCs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cell therapy, mesenchymal stem cell therapy, dilated cardiomyopathy, intravenous

4 terms

cell therapy medical

"panel discussions on cell therapy for heart failure, including delivery routes, cell types"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

mesenchymal stem cell therapy medical

"Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON"

Mesenchymal stem cell therapy uses adult stem cells that can develop into bone, cartilage, fat or other tissue and are delivered to patients to help repair damage and reduce inflammation; clinicians harvest, expand or modify these cells before administration. Investors care because these therapies aim to create new treatment options across many diseases, representing large market potential but also high risk tied to clinical trial outcomes, regulatory approval, manufacturing challenges and safety—like backing a promising but unproven repair crew.

dilated cardiomyopathy medical

"Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON"

A condition in which the heart’s main pumping chamber becomes enlarged and weak, so it can’t pump blood as efficiently — think of a water pump with a stretched-out rubber bladder that loses pressure. It matters to investors because that weakness drives demand for medications, devices, hospital services and long-term care, influences clinical trial and regulatory activity, and can affect health-care costs, insurer liability and workforce productivity in related companies.

intravenous medical

"Intravenous Delivery of Cells/Cell Products: The Magic Bullet?"

Intravenous means delivering a drug, fluid or substance directly into a vein so it goes straight into the bloodstream. For investors, that matters because intravenous products often act faster, require different manufacturing, regulatory steps and healthcare settings (like hospitals or clinics), and can affect pricing, adoption and revenue profiles in ways that differ from pills or topical treatments — like turning a slow-release delivery into a direct tap to the system.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Global CardioVascular Clinical Trialists (CVCT) Forum taking place December 8-10, 2025 in Washington, D.C. The CVCT Forum seeks to promote rigorous evidence generation and accelerate the global impact of cardiovascular clinical trials.

Panel Discussions – December 8, 2025

Cell Therapy Heart Failure Trials – Cells Deliver and Disease Specific Strategies
Is Cell Delivery Route Important?
Intravenous Delivery of Cells/Cell Products: The Magic Bullet? Dr. Joshua Hare

What Type of Cells?
Mesenchymal Stem Cell Therapy for Dilated Cardiomyopathy: Lessons from POSEIDON and the PATH AHEAD – Dr. Joshua Hare

How to Streamline Cell Therapy Innovation, Not Compromising the Level of Evidence
The CVCT Multi-Stakeholder Think Tank Debate
Dr. Nataliya Agafonova, Panelist

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e9e96d9c-d6c3-4aec-ba85-36631b520211
https://www.globenewswire.com/NewsRoom/AttachmentNg/f106bde7-972a-4687-a91e-03e924f409fc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Longeveron executives speak at the CVCT Forum (LGVN)?

Longeveron speakers will appear at the CVCT Forum in Washington, D.C., December 8-10, 2025.

Which Longeveron (LGVN) executives are presenting at the December 2025 CVCT Forum?

Dr. Joshua Hare (Chief Science Officer) and Dr. Nataliya Agafonova (Chief Medical Officer) are scheduled presenters.

What topics will Longeveron (LGVN) cover at the CVCT Forum panels on December 8, 2025?

Panels cover cell therapy heart failure trials, cell delivery routes, cell types (mesenchymal stem cell therapy), and innovation vs evidence standards.

Will Longeveron (LGVN) discuss results from POSEIDON and PATH AHEAD at the CVCT Forum?

Yes; Dr. Joshua Hare will discuss mesenchymal stem cell therapy for dilated cardiomyopathy with lessons from POSEIDON and PATH AHEAD.

How can investors learn more about Longeveron (LGVN) presentations at the CVCT Forum?

Investors can track the CVCT Forum agenda for session times and follow company updates for any public presentation materials.

Does Longeveron (LGVN) participation at CVCT Forum indicate new clinical data releases?

The announcement lists planned panel participation and topics but does not state any specific new clinical data releases or readouts.